Literature DB >> 26923384

Systemic Full Dose, Half Dose, and Catheter Directed Thrombolysis for Pulmonary Embolism. When to Use and How to Choose?

Mohsen Sharifi1,2.   

Abstract

OPINION STATEMENT: Treatment of pulmonary embolism (PE) is variable amongst different and even the same institutions. With the introduction of different forms of thrombolysis, catheter based interventions, and new oral anticoagulants, the treatment and decision-making process has become more complex. The different forms of classification of PE into massive, submassive, severe, moderate, intermediate high risk, intermediate low risk, and low risk have only added to this complexity. The main two reasons for such classifications have been to aid in assessment of patient prognosis and in the intent to carefully select patients who are high risk and would benefit from thrombolysis. The literature supports the use of thrombolysis in high risk patients albeit at the risk of a higher bleeding rate. It has been suggested that survival can improve in both massive and submassive PE with thrombolysis. Studies have shown a reduced risk of bleeding with reduction of the doses of the thrombolytic and anticoagulant agents while imparting the same beneficial effects seen in full dose thrombolysis. The opinion of this author is that treatment of massive and submassive forms of PE can become standardized, safe, streamlined, and simplified by using a lower dose of systemic thrombolysis for both and an anticoagulation regimen without the necessity for expensive approaches such as invasive catheter placement in the pulmonary circulation.

Entities:  

Keywords:  Catheter directed thrombolysis; Half dose thrombolysis; Pulmonary embolism; Pulmonary hypertension; Ultrasound facilitated

Year:  2016        PMID: 26923384     DOI: 10.1007/s11936-016-0456-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  25 in total

1.  A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study.

Authors:  Gregory Piazza; Benjamin Hohlfelder; Michael R Jaff; Kenneth Ouriel; Tod C Engelhardt; Keith M Sterling; Noah J Jones; John C Gurley; Rohit Bhatheja; Robert J Kennedy; Nilesh Goswami; Kannan Natarajan; John Rundback; Immad R Sadiq; Stephen K Liu; Narinder Bhalla; M Laiq Raja; Barry S Weinstock; Jacob Cynamon; Fakhir F Elmasri; Mark J Garcia; Mark Kumar; Juan Ayerdi; Peter Soukas; William Kuo; Ping-Yu Liu; Samuel Z Goldhaber
Journal:  JACC Cardiovasc Interv       Date:  2015-08-24       Impact factor: 11.195

2.  The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism.

Authors:  Tim Provias; David M Dudzinski; Michael R Jaff; Kenneth Rosenfield; Richard Channick; Joshua Baker; Ido Weinberg; Cameron Donaldson; Rajeev Narayan; Andrew N Rassi; Christopher Kabrhel
Journal:  Hosp Pract (1995)       Date:  2014-02

Review 3.  Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis.

Authors:  Zhu Zhang; Zhen-guo Zhai; Li-rong Liang; Fang-fang Liu; Yuan-hua Yang; Chen Wang
Journal:  Thromb Res       Date:  2013-12-23       Impact factor: 3.944

4.  Transforming and simplifying the treatment of pulmonary embolism: "safe dose" thrombolysis plus new oral anticoagulants.

Authors:  Mohsen Sharifi; Zoltan Vajo; Wilbur Freeman; Curt Bay; Mirali Sharifi; Frederic Schwartz
Journal:  Lung       Date:  2015-03-07       Impact factor: 2.584

5.  The successful use of low-dose recombinant tissue plasminogen activator for treatment of intracardiac/pulmonary thrombosis during liver transplantation.

Authors:  James D Boone; Saadia S Sherwani; Joshua C Herborn; Kinjal M Patel; Andre M De Wolf
Journal:  Anesth Analg       Date:  2010-12-02       Impact factor: 5.108

6.  Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism.

Authors:  Paul D Stein; Fadi Matta; David S Steinberger; Daniel C Keyes
Journal:  Am J Med       Date:  2011-11-24       Impact factor: 4.965

7.  Thrombolytic therapy for postoperative pulmonary embolism.

Authors:  J E Molina; D W Hunter; J W Yedlicka; F B Cerra
Journal:  Am J Surg       Date:  1992-04       Impact factor: 2.565

8.  Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.

Authors:  Saurav Chatterjee; Anasua Chakraborty; Ido Weinberg; Mitul Kadakia; Robert L Wilensky; Partha Sardar; Dharam J Kumbhani; Debabrata Mukherjee; Michael R Jaff; Jay Giri
Journal:  JAMA       Date:  2014-06-18       Impact factor: 56.272

9.  Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.

Authors:  S Z Goldhaber; G Agnelli; M N Levine
Journal:  Chest       Date:  1994-09       Impact factor: 9.410

10.  Acute pulmonary embolism treated with tissue plasminogen activator.

Authors:  S Z Goldhaber; D E Vaughan; J E Markis; A P Selwyn; M F Meyerovitz; J Loscalzo; D S Kim; C M Kessler; D L Dawley; G V Sharma
Journal:  Lancet       Date:  1986-10-18       Impact factor: 79.321

View more
  2 in total

1.  Saddle pulmonary embolus resulting in cardiovascular collapse requiring extracorporeal membrane oxygenation in a postoperative patient with endometrial cancer.

Authors:  David Samuel; Gregory M Gressel; Sara Isani; Akiva P Novetsky; Nicole S Nevadunsky
Journal:  Gynecol Oncol Rep       Date:  2018-03-16

2.  Effects of a Consensus-Based Pulmonary Embolism Treatment Algorithm and Response Team on Treatment Modality Choices, Outcomes, and Complications.

Authors:  Roman Melamed; Catherine A St Hill; Bjorn I Engstrom; David M Tierney; Claire S Smith; Vincent K Agboto; Brynn E Weise; Peter M Eckman; Nedaa Skeik
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.